Abstract:Purpose. Human pregnane X receptor (hPXR) has a key role in regulating metabolism of endogenous and exogenous substances. Identification of novel hPXR activators among commercial drugs aids in avoiding drug-drug interactions with future co-administered drugs. Methods. Virtual screening with Structure-Activity Relationship (SAR) models has been applied for identification of novel hPXR activators. Ligand-based modeling was conducted with Discover Studio (DS) 2.1. Bayesian classification models were generated with a training set comprising 177 compound, and were validated with a test set with 145 compounds. The activities of commonly prescribed drugs from SCUT database were predicted with one of the Bayesian models. Cell-based luciferase reporter assay was used for evaluation of chemical-mediated hPXR activation. HepG2 cells were co-transfected with PXR expression vector and CYP2B6-luciferase reporter construct. 0.1% DMSO solution was used as vehicle control while rifampicin as the positive control. The binding mode between an experimental validated hPXR modulators and hPXR were studied by docking a ligand into hPXR binding domain (PDB ID: 1NRL) with programs FlexX and SurFlex. Results. The Bayesian models showed specificity and overall prediction accuracy up to 0.92 and 0.69 for test set compounds. One Bayesian model with specificity of 0.92 was selected to screen the SCUT database and retrieved 113 hits. 17 compounds were chosen for in vitro testing. The luciferase reporter assay confirmed that seven drugs, i.e., fluticasone, nimodipine, nisoldipine, beclomethasone, finasteride, flunisolide, and megestrol were previously unidentified potent or moderate hPXR activators, with 2.7 to 18.5- fold increase in luciferase activity compared to vehicle control. Conclusion. In this study, virtual screening based on SAR models successfully identified seven novel hPXR activators among FDA approved and commonly prescribed drugs. The same approach could be used for identification of activators or inhibitors of other protein targets.

[Coexpression of PXRLBD with SRC88 and Construction of Equilibrium Dialysis Model of Screening PXR Ligands].

3d-Qsar And Docking Studies Of Estrogen Compounds Based On Estrogen Receptor Beta

Establishment of cell models for PXR, FXR and LXRαagonists high-throughput screening based on reporter gene assay

Progresses of researches on the correlation between pregnane X receptor and CYP3A

Identification and Validation of Novel Human Pregnane X Receptor Activators among Prescribed Drugs Via Ligand-Based Virtual Screening

Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study.

Establishment of hPXR Mediated Reporter Gene Model for UGT1A1 and Its Application

Insight into the molecular recognition of human and polar bear pregnane X receptor by three organic pollutants using molecular docking and molecular dynamics simulations

Investigation of Ligand Selectivity in CYP3A7 by Molecular Dynamics Simulations

In Vitro and in Silico Assessment of Endocrine Disrupting Effects of Food Contaminants Through Pregnane X Receptor

Novel Estrogen Receptor Ligands and Their Structure-Activity Relationship Evaluated by Scintillation Proximity Assay for High-Throughput Screening

Immobilization of peroxisome proliferator-activated receptor gamma and the application in screening modulators of the receptor from herbal medicine

A Mechanism-Based Pharmacokinetic/pharmacodynamic Model for CYP3A1/2 Induction by Dexamethasone in Rats

Identification of Hpxr Modulators Via Sar-Based Virtual Screening

THE PREGNANE X RECEPTOR BINDS TO RESPONSE ELEMENTS IN A GENOMIC CONTEXT-DEPENDENT MANNER, AND PXR ACTIVATOR RIFAMPICIN SELECTIVELY ALTERS THE BINDING AMONG TARGET GENES

Ligand‐binding Regulation of LXR/RXR and LXR/PPAR Heterodimerizations: SPR Technology‐based Kinetic Analysis Correlated with Molecular Dynamics Simulation

Simultaneous Substitution of Phenylalanine-305 and Aspartate-318 of Rat Pregnane X Receptor with the Corresponding Human Residues Abolishes the Ability to Transactivate the CYP3A23 Promoter

LASSO-ing Potential Nuclear Receptor Agonists and Antagonists: A New Computational Method for Database Screening

Ensemble Docking Approach to Mitigate Pregnane X Receptor-Mediated CYP3A4 Induction Risk

Dietary phytochemicals as modulators of human pregnane X receptor

Activation of steroid hormone receptors: Shed light on the in silico evaluation of endocrine disrupting chemicals